Breaking News

Mustang Bio to Participate in Three September 2021 Investor Conferences | News

WORCESTER, Mass., Sept. 09, 2021 (World NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a scientific-phase biopharmaceutical company centered on translating today’s professional medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, good tumors and exceptional genetic conditions, nowadays introduced that Manuel Litchman, M.D., President and Chief Executive Officer, will take part in 3 virtual trader conferences in September 2021.

Details of the events are as follows:

H.C. Wainwright 23rd Once-a-year World-wide Investment Meeting: The company’s presentation will be out there for on-desire viewing on Mustang’s web-site commencing on Monday, September 13, 2021, at 7:00 a.m. ET and will continue to be readily available on the Events web site of the Investor Relations part of Mustang’s site,

www.mustangbio.com

, for approximately 30 times after the conference. The business will take part in a single-on-one particular conferences during the meeting as properly.Oppenheimer Tumble Health care Existence Sciences & MedTech Summit: The company will participate in a fireplace chat on Monday, September 20, 2021, at 12:25 p.m. ET and will participate in just one-on-one particular conferences for the duration of the meeting. A webcast of the company’s chat will be offered on the Gatherings webpage of the Investor Relations area of Mustang’s site,

www.mustangbio.com

, for close to 30 times immediately after the meeting.Cantor International Healthcare Convention: The enterprise will take part in a fireplace chat on Monday, September 27, 2021, at 10:40 a.m. ET and will take part in one-on-a single conferences in the course of the convention. A webcast of the company’s chat will be accessible on the Occasions web page of the Trader Relations part of Mustang’s site,

www.mustangbio.com

, for roughly 30 times just after the meeting.

About Mustang Bio Mustang Bio, Inc. is a medical-stage biopharmaceutical firm targeted on translating today’s health-related breakthroughs in mobile and gene therapies into probable cures for hematologic cancers, stable tumors and exceptional genetic illnesses. Mustang aims to obtain legal rights to these technologies by licensing or or else acquiring an possession desire, to fund investigate and enhancement and to outlicense or provide the technologies to sector. Mustang has partnered with prime medical establishments to progress the progress of Automobile T therapies throughout multiple cancers, as properly as a lentiviral gene remedy for X-joined severe merged immunodeficiency. Mustang is registered under the Securities Trade Act of 1934, as amended, and documents periodic stories with the U.S. Securities and Exchange Commission (“SEC”). Mustang was launched by Fortress Biotech, Inc. (NASDAQ: FBIO). For more details, take a look at www.mustangbio.com.

Forward‐Looking Statements This press launch may have “forward-searching statements” within just the meaning of Portion 27A of the Securities Act of 1933 and Portion 21E of the Securities Exchange Act of 1934, each and every as amended. This kind of statements include, but are not minimal to, any statements relating to our advancement approach and product growth courses and any other statements that are not historic details. Ahead-looking statements are based on management’s present-day expectations and are subject matter to threats and uncertainties that could negatively have an effect on our business enterprise, functioning final results, monetary affliction and stock benefit. Things that could trigger genuine outcomes to vary materially from people at the moment predicted include: pitfalls relating to our expansion tactic our potential to obtain, complete below, and sustain financing and strategic agreements and associations risks relating to the effects of exploration and progress activities challenges relating to the timing of starting and finishing scientific trials uncertainties relating to preclinical and clinical tests our dependence on third-celebration suppliers our capability to entice, integrate and retain vital personnel the early stage of products below advancement our need for substantial extra money govt regulation patent and mental home issues competitors as nicely as other dangers described in our SEC filings. We expressly disclaim any obligation or enterprise to launch publicly any updates or revisions to any forward-seeking statements contained herein to mirror any modify in our expectations or any improvements in occasions, conditions or situation on which any this kind of statement is centered, besides as required by regulation, and we declare the safety of the safe harbor for ahead-searching statements contained in the Non-public Securities Litigation Reform Act of 1995.

Organization Contacts: Jaclyn Jaffe and Invoice Begien Mustang Bio, Inc. (781) 652-4500 ir@mustangbio.com

Investor Relations Speak to: Daniel Ferry LifeSci Advisors, LLC (617) 430-7576 daniel@lifesciadvisors.com

Media Relations Call: Tony Plohoros 6 Levels (908) 591-2839 tplohoros@6degreespr.com

Copyright 2021 GlobeNewswire, Inc.